COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/109 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849228020187922432 |
|---|---|
| author | V. A. Sulimov D. A. Napalkov A. A. Sokolova |
| author_facet | V. A. Sulimov D. A. Napalkov A. A. Sokolova |
| author_sort | V. A. Sulimov |
| collection | DOAJ |
| description | Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons. |
| format | Article |
| id | doaj-art-705c92c9ac504dfd84272acd43b9f705 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-705c92c9ac504dfd84272acd43b9f7052025-08-23T10:00:16ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-019443343810.20996/1819-6446-2013-9-4-433-438108COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTSV. A. Sulimov0D. A. Napalkov1A. A. Sokolova2I.M. Sechenov First Moscow State Medical University, MoscowI.M. Sechenov First Moscow State Medical University, MoscowI.M. Sechenov First Moscow State Medical University, MoscowIndirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons.https://www.rpcardio.online/jour/article/view/109atrial fibrillationstroke preventionhemorrhagic complicationsapixabandabigatranrivaroxaban |
| spellingShingle | V. A. Sulimov D. A. Napalkov A. A. Sokolova COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Рациональная фармакотерапия в кардиологии atrial fibrillation stroke prevention hemorrhagic complications apixaban dabigatran rivaroxaban |
| title | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS |
| title_full | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS |
| title_fullStr | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS |
| title_full_unstemmed | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS |
| title_short | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS |
| title_sort | comparative efficacy and safety of new oral anticoagulants |
| topic | atrial fibrillation stroke prevention hemorrhagic complications apixaban dabigatran rivaroxaban |
| url | https://www.rpcardio.online/jour/article/view/109 |
| work_keys_str_mv | AT vasulimov comparativeefficacyandsafetyofneworalanticoagulants AT danapalkov comparativeefficacyandsafetyofneworalanticoagulants AT aasokolova comparativeefficacyandsafetyofneworalanticoagulants |